{"disease":{"id":"measurable-residual-disease-mrd","name":"measurable residual disease mrd"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07264010","title":"Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":87,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT04827745","title":"Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}